ProFactor Pharma

Transforming treatment availability for Haemophilia A

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia A. 

Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.

Recent News

World Hemophilia Day

On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day. The theme of the event this year is “Equitable access for all: recognizing all bleeding disorders”. The World Federation...

read more